EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression

BACKGROUND: Increasing evidence suggests the involvement of enhancer of zeste homologue 2 (EZH2) in chemoresistance of cancer treatment. Nevertheless, its function and molecular mechanisms in gastric cancer (GC) chemoresistance are still not well elucidated. MATERIALS AND METHODS: In the present stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chenyu, Li, Xingwang, Zhang, Junjie, Ge, Zheng, Chen, Hejin, Hu, Junhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225849/
https://www.ncbi.nlm.nih.gov/pubmed/30464532
http://dx.doi.org/10.2147/OTT.S180131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225849/
https://www.ncbi.nlm.nih.gov/pubmed/30464532
http://dx.doi.org/10.2147/OTT.S180131

Ejemplares similares